--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-24-018735" form_type: "8-K" ticker: "RCEL" cik: "0001762303" company_name: "AVITA Medical, Inc." filed_at: "2024-02-22T23:59:59+00:00" generated_at: "2026-06-05T19:52:52.321769+00:00" event_type: "earnings" sentiment: "positive" materiality_score: 0.7 calibrated_materiality_score: 0.7 confidence: "high" source: SEC EDGAR --- # AVITA Medical Q4 commercial revenue up 50% to $14.1M; guides FY2024 rev $78.5-84.5M ## Summary - Commercial revenue Q4 $14.1M (+50% YoY); gross margin 87.3%. - Full-year 2023 commercial revenue $49.8M (+46% YoY); net loss $35.4M ($1.40/share). - Q1 2024 revenue guidance $14.8-15.6M; FY2024 guidance $78.5-84.5M (57-69% growth). - Expects RECELL GO FDA launch May 31, 2024; sales team to expand to 108. - Targeting cashflow breakeven and GAAP profitability no later than Q3 2025. ## SEC filing metadata - accession: 0000950170-24-018735 - form_type: 8-K - ticker: RCEL - cik: 0001762303 - company_name: AVITA Medical, Inc. - filed_at: 2024-02-22T23:59:59+00:00 - event_type: earnings - sentiment: positive - materiality_score: 0.7 - calibrated_materiality_score: 0.7 - confidence: high - sec_items: 2.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/rcel-20240222.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-24-018735 - JSON: https://secwatch.observer/filing/0000950170-24-018735.json - Plain text: https://secwatch.observer/filing/0000950170-24-018735.txt ## Key facts - Earnings Releases AVITA Medical, Inc. reported Fourth Quarter 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS Net loss was $7.1 million, or a loss of $0.28 per basic and diluted share. - Period: Fourth Quarter 2023 - Revenue: Commercial revenue increased approximately 50% to $14.1 million - EPS: Net loss was $7.1 million, or a loss of $0.28 per basic and diluted share - Result: reported results source text: reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8 evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm - Earnings Releases AVITA Medical, Inc. reported first quarter 2024 results: revenue Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million. Guidance initiated. - Period: first quarter 2024 - Revenue: Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million - Guidance: initiated - Result: guidance update source text: Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth of approximately 42% to approximately 50% over the same period in the prior year evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm - Earnings Releases AVITA Medical, Inc. reported full-year 2024 results: revenue Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million. Guidance initiated. - Period: full-year 2024 - Revenue: Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million - Guidance: initiated - Result: guidance update source text: Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million, reflecting growth of approximately 57% to approximately 69% over the full-year 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm - Earnings Releases AVITA Medical, Inc. reported Full-Year 2023 results: revenue Commercial revenue increased by 46% to $49.8 million, EPS Net loss for the full-year 2023 was $35.4 million, or a loss of $1.40 per basic and diluted share. - Period: Full-Year 2023 - Revenue: Commercial revenue increased by 46% to $49.8 million - EPS: Net loss for the full-year 2023 was $35.4 million, or a loss of $1.40 per basic and diluted share - Result: reported results source text: 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8 million compared to the same period in 2022 • Gross profit margin of 84.5% • As of December 31, 2023, approximately $89.1 million in cash, cash equivalents, and evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm - Earnings Releases AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS loss of $0.28 per basic and diluted share. - Period: fourth quarter and full-year ended December 31, 2023 - Revenue: Commercial revenue increased approximately 50% to $14.1 million - EPS: loss of $0.28 per basic and diluted share - Result: reported results source text: reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8 evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.